Pharma Report

Zevra Therapeutics (ZVRA) Investment Analysis Authored by Generative Artificial Intelligence We used a latest generation #ChatGPT (#GenAI) to co-author a concise investment analysis of Zevra Therapeutics, a small cap biotech. The following is an extract of generated text: Zevra Therapeutics (ZVRA) is a nimble rare disease therapeutics company with a proven record of bringing new therapies to patients. The company's pipeline includes arimoclomol, a first-in-class molecule targeting Niemann-Pick type C disease, and ZV-64, a novel small molecule inhibitor of the STAT3 pathway. In Q1 23, Zevra reported a net loss of $12 million, compared to a net loss of $2 million in the same period of the previous year. The company had cash and cash equivalents of $95 million as of March 31, 23. Arimoclomol is the company's lead product candidate, which is in late-stage development for Niemann-Pick type C disease. The company has completed a Phase 3 clinical trial for arimoclomol and is preparing to submit a New Drug Application (NDA) to the FDA. Continue reading at #VirtualPharma: https://lnkd.in/e2BnC6Cm 🚀 🚀 🚀 🚀 🚀 #investment #pipeline #biotech #artificialintelligence

Exploring the potential of #GenAI professional co-authoring skills as a Co-Pilot. Current generation of centralized Generative AI tend to hallucinate. Read only for fun, and at your own #Risk! #ai 👽 👾 🤖 🌏 ⁉